Zelluna ASA
18.00
NOK
-0.30
(-1.64%)
Zelluna ASA
OSL:ZLNA
(Euronext Oslo)
Recent
price
18.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Quarterly Revenue
NOK
•
in mil. unless spec.Quarterly Earnings Per Share
NOK
•
in mil. unless spec.Quarterly Dividends Per Share
NOK
•
in mil. unless spec.- Similar Companies
- Business
- Zelluna ASA is a biotechnology company that develops TCR-based cellular immunotherapies for the treatment of solid cancers, leveraging allogeneic NK cell platforms to create off-the-shelf therapies targeting tumor-associated antigens. The company operates globally with headquarters in Oslo, Norway, and was founded in 2016. Zelluna’s product focus centers on TCR-based, NK-cell–driven cancer therapies deployed as off-the-shelf cellular products, with a pipeline aimed at expanding access to targeted immunotherapies for solid tumors. Main products and services - T-cell receptor (TCR)–based cellular immunotherapies: allogeneic NK-cell platforms engineered to express tumor-targeting TCRs; off-the-shelf TCR-NK products intended for broad solid-tumor indications; collaborations and manufacturing processes designed to enable scalable, ready-to-use cell therapies. - Pipeline development programs: lead candidates and subsequent product embodiments targeting validated cancer antigens; research and development services around TCR discovery, characterization, and optimization; partnerships to expand antigen coverage and clinical indications. - Platform development and manufacturing support: optimization of allogeneic NK-cell biology, TCR integration, manufacturing workflows, quality controls, and translational activities to support clinical development and potential commercialization. Latest major company changes - Strategic combination and corporate developments: in 2025, Zelluna completes a business combination with Ultimovacs ASA, broadening its strategic footprint and funding basis; subsequent financial updates highlight expanded clinical strategy and pipeline advancement, including acquisitions to enrich TCR targets and therapeutic breadth. - Pipeline and partnerships: in 2025, Zelluna reports expanded collaborations and partnerships to advance TCR-NK therapies, including new antigen targets and potential licensing or collaboration agreements to accelerate clinical development and manufacturing scale. - Product and platform evolution: ongoing enhancements to the TCR-NK CR-N platform, with emphasis on off-the-shelf scalability, broader tumor-detection capabilities, and regulatory strategy across key markets; expanded clinical footprint through UK and other regional development activities. Industry and business segments - Industry: biotechnology; immuno-oncology; cellular therapy; regenerative medicine. - Segments: research and development of TCR-based NK-cell therapies; early-stage clinical development support; collaboration and licensing activities; potential manufacturing and supply chain enablement for off-the-shelf cellular products. Geographic operations and corporate structure - Headquarters: Oslo, Norway. - Global operations: targeted clinical development and partnerships across Europe and other regions; worldwide outreach for research collaborations and potential commercialization channels. - Subsidiaries/affiliates: operates through a network of collaborations and licensing arrangements, with corporate structure oriented toward biotech research, clinical development, and strategic partnerships. Founding year and headquarters - Founded in 2016; headquarters in Oslo, Norway. Note: This description reflects Zelluna’s focus on allogeneic TCR-NK therapies for solid tumors, its 2016 inception, Oslo base, and the recent strategic developments around 2025 including the business combination and pipeline expansion. For the most up-to-date and precise details on product names, target antigens, and current partnerships or acquisitions, refer to Zelluna’s official communications and recent investor updates. [sources: latest public company materials and industry coverage]